Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland

Misonix Announces New Distribution Agreement for United Kingdom and Republic
of Ireland

FARMINGDALE, N.Y., Oct. 8 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq:
MSON), a developer of minimally invasive ultrasonic medical device technology,
which in Europe is used for the ablation of tumors and worldwide for other
acute health conditions, has entered into a new, three year distribution
agreement with WeightJust Ltd., based in Banbury, England, for the
distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator.

The agreement provides WeightJust with the exclusive rights to sell in the
United Kingdom and the Republic of Ireland and includes minimum purchase
requirements.

WeightJust has significant experience in the distribution of medical devices
and capital equipment with specialized expertise in neurosurgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient
removal of both hard and soft tumors while sparing most vessels. In addition,
OsteoSculpt(TM) bone shaving technology can be employed with the SonaStar to
safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making
precise cuts through bone and hard tissue while largely preserving delicate
soft tissue structures. It offers the convenience and speed of a power
instrument without the potential hazards associated with rotary sharps.

"Misonix is pleased to add WeightJust to our growing sales organization.
WeightJust's established position in the neurosurgery and general surgery
distribution channels should prove beneficial for both companies as we expand
our presence in the United Kingdom and the Republic of Ireland," said Michael
A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix:
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets
therapeutic ultrasonic medical devices and laboratory equipment. Misonix's
therapeutic ultrasonic platform is the basis for several innovative medical
technologies. Addressing a combined market estimated to be in excess of $3
billion annually; Misonix's proprietary ultrasonic medical devices are used
for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery,
and other surgical and medical applications. Additional information is
available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath
Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com

SOURCE Misonix, Inc.

Richard Zaremba, Misonix, +1-631-694-9555, invest@misonix.com, or Investor
Relations Contact, Kevin McGrath, Cameron Associates, Inc., +1-212-245-4577,
Kevin@cameronassoc.com